60 DEGREES PHARMACEUTICALS, INC. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
60 Degrees Pharmaceuticals (market cap ~$3.3M) is pursuing FDA label expansion of ARAKODA (tafenoquine) from malaria prophylaxis into babesiosis treatment via sNDA. The company reports Q2 2026 ARAKODA net product revenue of $208k (+106% YoY) with ~27% gross margin ($57k). July 2026 financing raised $1.0M gross at $1.74/share; post-financing cash ~$1.0M with ~$5.0M 6-month operating burn creates runway into early October 2026. Development rationale includes non-clinical data, 4-patient case series showing cure in refractory immunosuppressed babesiosis, and potential market of 350,000 treatment patients (~$180M WAC opportunity vs. $90M malaria base, 3x asset potential).
Why this rating
Label expansion of approved product into high-unmet-need orphan indication is meaningful; babesiosis opportunity could materially increase ARAKODA value. However, significant cash depletion (runway into October), warrant dilution (~3.09M warrants vs. ~3.51M common), execution risk on regulatory pathway, and early-stage development (interim analysis pending) temper upside. For $3.3M-cap company, $180M revenue potential is transformational if realized, but probability is unproven.
Tradability signal
NO TRADE
No trade: price $0.03 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.03 | +10 min · unknown $0.03 ▲ 0.00% | +30 min · unknown $0.03 ▲ 0.00% | +1 hr · unknown $0.03 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.